Of note, de novo ALK resistance mutations, as well as pre-existing genetic aberrations leading to ALK-TKI therapy failure are generally rare (<3–5% of ALK-resistant NSCLC) [24]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.